These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 11145192

  • 1. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M.
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [Abstract] [Full Text] [Related]

  • 2. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
    Profit L, Eagling VA, Back DJ.
    AIDS; 1999 Sep 10; 13(13):1623-7. PubMed ID: 10509562
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
    Lucia MB, Rutella S, Leone G, Vella S, Cauda R.
    J Acquir Immune Defic Syndr; 2001 Aug 01; 27(4):321-30. PubMed ID: 11468419
    [Abstract] [Full Text] [Related]

  • 6. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A, Zhang Y, Unadkat JD, Mao Q.
    J Pharmacol Exp Ther; 2004 Jul 01; 310(1):334-41. PubMed ID: 15007102
    [Abstract] [Full Text] [Related]

  • 7. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.
    Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D.
    J Acquir Immune Defic Syndr; 2003 Aug 15; 33(5):551-6. PubMed ID: 12902797
    [Abstract] [Full Text] [Related]

  • 8. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY, Park YJ, Lee BM, Yoon S.
    Anticancer Res; 2019 Jul 15; 39(7):3757-3765. PubMed ID: 31262902
    [Abstract] [Full Text] [Related]

  • 9. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H.
    Biochem Biophys Res Commun; 2013 Sep 20; 439(2):221-7. PubMed ID: 23981805
    [Abstract] [Full Text] [Related]

  • 10. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.
    Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS.
    Mol Pharmacol; 1999 Aug 20; 56(2):383-9. PubMed ID: 10419558
    [Abstract] [Full Text] [Related]

  • 11. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
    Patel J, Buddha B, Dey S, Pal D, Mitra AK.
    Am J Ther; 2004 Aug 20; 11(4):262-77. PubMed ID: 15266218
    [Abstract] [Full Text] [Related]

  • 12. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
    Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H.
    Biol Pharm Bull; 2009 Sep 20; 32(9):1588-93. PubMed ID: 19721237
    [Abstract] [Full Text] [Related]

  • 13. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
    van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD.
    AIDS; 2001 Mar 09; 15(4):483-91. PubMed ID: 11242145
    [Abstract] [Full Text] [Related]

  • 14. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK, Boritzki TJ, Bloom LA.
    Antimicrob Agents Chemother; 1997 Oct 09; 41(10):2159-64. PubMed ID: 9333041
    [Abstract] [Full Text] [Related]

  • 15. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
    Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM.
    Drug Metab Dispos; 2000 Mar 09; 28(3):329-34. PubMed ID: 10681378
    [Abstract] [Full Text] [Related]

  • 16. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
    Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ.
    Pharm Res; 2002 Jul 09; 19(7):1038-45. PubMed ID: 12180537
    [Abstract] [Full Text] [Related]

  • 17. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
    Drewe J, Gutmann H, Fricker G, Török M, Beglinger C, Huwyler J.
    Biochem Pharmacol; 1999 May 15; 57(10):1147-52. PubMed ID: 11230802
    [Abstract] [Full Text] [Related]

  • 18. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
    Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD.
    Drug Metab Dispos; 2002 May 15; 30(5):479-82. PubMed ID: 11950774
    [Abstract] [Full Text] [Related]

  • 19. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K, Trdan T, Trontelj J, Kristl A.
    Biopharm Drug Dispos; 2010 Nov 15; 31(8-9):495-505. PubMed ID: 21104925
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
    Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2001 Apr 15; 59(4):806-13. PubMed ID: 11259625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.